Avicanna Inc (AVCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avicanna Inc (AVCN) has a cash flow conversion efficiency ratio of -0.075x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-956.36K ≈ $-691.82K USD) by net assets (CA$12.79 Million ≈ $9.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AVCN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Avicanna Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Avicanna Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avicanna Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avicanna Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WIN Metals Ltd
AU:WIN
|
-0.183x |
|
OSR Holdings Inc
NASDAQ:OSRH
|
-0.008x |
|
Gold By Gold
PA:ALGLD
|
0.083x |
|
PZ Cormay SA
WAR:CRM
|
-0.019x |
|
Intraco Penta Tbk
JK:INTA
|
-0.008x |
|
Elysee Development Corp
V:ELC
|
0.139x |
|
exax Inc
KQ:060230
|
-0.030x |
|
Carnegie Clean Energy Limited
F:CNM1
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Avicanna Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Avicanna Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Avicanna Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$11.39 Million ≈ $8.24 Million |
CA$-1.18 Million ≈ $-854.49K |
-0.104x | +60.32% |
| 2024-12-31 | CA$9.74 Million ≈ $7.05 Million |
CA$-2.55 Million ≈ $-1.84 Million |
-0.261x | -48.44% |
| 2023-12-31 | CA$7.97 Million ≈ $5.77 Million |
CA$-1.40 Million ≈ $-1.02 Million |
-0.176x | +91.81% |
| 2022-12-31 | CA$3.46 Million ≈ $2.50 Million |
CA$-7.44 Million ≈ $-5.38 Million |
-2.150x | -27.33% |
| 2021-12-31 | CA$6.91 Million ≈ $5.00 Million |
CA$-11.66 Million ≈ $-8.44 Million |
-1.688x | -68.10% |
| 2020-12-31 | CA$13.91 Million ≈ $10.06 Million |
CA$-13.97 Million ≈ $-10.11 Million |
-1.004x | -54.28% |
| 2019-12-31 | CA$29.88 Million ≈ $21.61 Million |
CA$-19.45 Million ≈ $-14.07 Million |
-0.651x | -244.11% |
| 2018-12-31 | CA$26.38 Million ≈ $19.08 Million |
CA$-4.99 Million ≈ $-3.61 Million |
-0.189x | +92.54% |
| 2017-12-31 | CA$841.07K ≈ $608.42K |
CA$-2.13 Million ≈ $-1.54 Million |
-2.537x | -506.93% |
| 2016-12-31 | CA$-29.76K ≈ $-21.53K |
CA$-18.55K ≈ $-13.42K |
0.623x | -- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more